RevenueShares Ultra Dividend ETF
Taking Stock of Radius Health’s Financial Performance
In 3Q17, Radius Health (RDUS) generated revenue of $13.4 million. Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue.
Taking Stock of Radius Health’s Licensing Agreements
The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.
A Strong Pipeline of Drugs Bodes Well for Radius Health
The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.
Analysts’ Ratings for Radius Health and Its Peers in January
In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.
A Comparative Analysis of PTH and DWAQ
PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.
An Overview of PTH’s Pharmaceutical and Biotechnology Holdings
PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.
Moving Averages of XBI’s Holdings Have Improved
The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.
On a Bullish Day, IBB Outperformed XLV
The iShares Nasdaq Biotechnology ETF (IBB) rose 4.4%, the Health Care Select Sector SPDR ETF (XLV) rose 2.2%, and the SPDR S&P 500 ETF (SPY) moved up by 1.5% on October 15.
Radius Continued to Fall despite Positive Data on Osteoporosis
Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.
ANAC Leads Pharmaceuticals Valuations in the Week Ending July 17
Anacor Pharmaceuticals (ANAC) with a 71.92% jump in its price for the week ending July 17, 2015, has helped to push the average PVB of the pharmaceutical sector to 11.62.